Howe & Rusling Inc. Has $8.11 Million Position in Edwards Lifesciences Corporation $EW

Posted by Geri Gentry on Jul 5th, 2026

Howe & Rusling Inc. raised its holdings in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 17.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 101,227 shares of the medical research company’s stock after purchasing an additional 15,364 shares during the period. Howe & Rusling Inc.’s holdings in Edwards Lifesciences were worth $8,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the period. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after acquiring an additional 989,533 shares during the period. Norges Bank bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $803,686,000. Morgan Stanley raised its position in Edwards Lifesciences by 12.4% in the fourth quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after purchasing an additional 804,942 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Edwards Lifesciences by 66.1% in the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EW. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Evercore reiterated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $96.39.

Read Our Latest Analysis on Edwards Lifesciences

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $94.31 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $54.31 billion, a price-to-earnings ratio of 50.17, a P/E/G ratio of 2.37 and a beta of 0.86. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $94.47. The firm’s 50-day moving average price is $85.61 and its two-hundred day moving average price is $83.57.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the business posted $0.64 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $91.40, for a total value of $56,576.60. Following the transaction, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,693,565.40. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,977 shares of company stock valued at $4,921,803 in the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.